BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by HC Wainwright

BioXcel Therapeutics (NASDAQ:BTAI)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 304.41% from the stock’s current price.

Separately, UBS Group reissued a “neutral” rating and set a $4.00 target price (down previously from $9.00) on shares of BioXcel Therapeutics in a research report on Wednesday, February 21st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, BioXcel Therapeutics presently has a consensus rating of “Hold” and an average price target of $16.86.

BioXcel Therapeutics Stock Down 0.7 %

BTAI opened at $2.72 on Monday. The firm has a 50 day moving average price of $3.02 and a 200 day moving average price of $3.25. The company has a market cap of $82.63 million, a PE ratio of -0.44 and a beta of 0.42. BioXcel Therapeutics has a 1 year low of $1.91 and a 1 year high of $29.56. The company has a debt-to-equity ratio of 16.52, a quick ratio of 2.45 and a current ratio of 2.51.

Institutional Trading of BioXcel Therapeutics

Large investors have recently bought and sold shares of the company. US Bancorp DE grew its position in BioXcel Therapeutics by 42,542.4% in the second quarter. US Bancorp DE now owns 14,072 shares of the company’s stock valued at $94,000 after acquiring an additional 14,039 shares in the last quarter. Bank of New York Mellon Corp grew its position in BioXcel Therapeutics by 13.2% in the third quarter. Bank of New York Mellon Corp now owns 128,022 shares of the company’s stock valued at $324,000 after acquiring an additional 14,901 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in BioXcel Therapeutics by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 33,940 shares of the company’s stock valued at $86,000 after acquiring an additional 16,032 shares in the last quarter. Profund Advisors LLC grew its position in BioXcel Therapeutics by 29.2% in the second quarter. Profund Advisors LLC now owns 35,475 shares of the company’s stock valued at $236,000 after acquiring an additional 8,013 shares in the last quarter. Finally, E Fund Management Co. Ltd. acquired a new stake in BioXcel Therapeutics in the second quarter valued at approximately $71,000. Institutional investors and hedge funds own 90.86% of the company’s stock.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.